Bafna Pharmaceuticals Ltd vs Colinz Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 131.85 as of 05 May 15:30 . The P/E Ratio of Bafna Pharmaceuticals Ltd changed from 55.8 on March 2021 to 42.6 on March 2025 . This represents a CAGR of -5.26% over 5 yearsThe P/E Ratio of Colinz Laboratories Ltd changed from 12.9 on March 2021 to 36.8 on March 2025 . This represents a CAGR of 23.33% over 5 years The Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 324.8 crore on March 2021 to ₹ 177.42 crore on March 2025 . This represents a CAGR of -11.39% over 5 yearsThe Market Cap of Colinz Laboratories Ltd changed from ₹ 3.47 crore on March 2021 to ₹ 33.11 crore on March 2025 . This represents a CAGR of 57.01% over 5 years The revenue of Bafna Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 39.51 crore. This represent the decline of -100% The revenue of Colinz Laboratories Ltd for the Mar '26 is ₹ 1.92 crore as compare to the Dec '25 revenue of ₹ 1.51 crore. This represent the growth of 27.15% The ebitda of Bafna Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 4.27 crore. This represent the decline of -100% The ebitda of Colinz Laboratories Ltd for the Mar '26 is ₹ 0.27 crore as compare to the Dec '25 ebitda of ₹ 0.18 crore. This represent the growth of 50% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ -0.72 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Colinz Laboratories Ltd changed from ₹ 0.14 crore to ₹ 0.17 crore over 8 quarters. This represents a CAGR of 10.19% The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Colinz Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

About Colinz Laboratories Ltd

Colinz Laboratories Limited, was incorporated as a Private Limited Company in 1986.
The Company got converted into Public Limited Company in 1995, which however started their manufacturing and marketing activities in 1995.
The Company manufactures a wide variety of pharmaceutical formulations in the dosage forms of tablets, capsules, granules, liquid orals, injectables, ointments, creams etc.
The Company is having certain specialized products for Gynaecology, Cardiology, Gastroentrology etc.
Since, the Company falls under the MSME sector, it established reputation as a quality supplier of medicines in the domestic market, wherever the Company has operation. Apart from this, the Company has a WHO compliant plant at Sinnar.

FAQs for the comparison of Bafna Pharmaceuticals Ltd and Colinz Laboratories Ltd

Which company has a larger market capitalization, Bafna Pharmaceuticals Ltd or Colinz Laboratories Ltd?

Market cap of Bafna Pharmaceuticals Ltd is 311 Cr while Market cap of Colinz Laboratories Ltd is 6 Cr

What are the key factors driving the stock performance of Bafna Pharmaceuticals Ltd and Colinz Laboratories Ltd?

The stock performance of Bafna Pharmaceuticals Ltd and Colinz Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bafna Pharmaceuticals Ltd and Colinz Laboratories Ltd?

As of May 5, 2026, the Bafna Pharmaceuticals Ltd stock price is INR ₹131.85. On the other hand, Colinz Laboratories Ltd stock price is INR ₹50.0.

How do dividend payouts of Bafna Pharmaceuticals Ltd and Colinz Laboratories Ltd compare?

To compare the dividend payouts of Bafna Pharmaceuticals Ltd and Colinz Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.